Your browser doesn't support javascript.
loading
It's difficult, but important, to make negative predictions.
Williams, Richard V; Amberg, Alexander; Brigo, Alessandro; Coquin, Laurence; Giddings, Amanda; Glowienke, Susanne; Greene, Nigel; Jolly, Robert; Kemper, Ray; O'Leary-Steele, Catherine; Parenty, Alexis; Spirkl, Hans-Peter; Stalford, Susanne A; Weiner, Sandy K; Wichard, Joerg.
Afiliação
  • Williams RV; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK. Electronic address: richard.williams@lhasalimited.org.
  • Amberg A; Sanofi-Aventis Deutschland GmbH, R&D DSAR/Preclinical Safety FF, Industriepark Hoechst, Bldg. H823, D-65926 Frankfurt am Main, Germany.
  • Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
  • Coquin L; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.
  • Giddings A; GlaxoSmithKline Pre-Clinical Development, Park Road, Ware, Hertfordshire SG12 0DP, UK.
  • Glowienke S; Novartis Pharma AG, Pre-clinical Safety, Werk Klybeck, CH-4057 Basel, Switzerland.
  • Greene N; Compound Safety Prediction, Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT 06340, USA.
  • Jolly R; Health/Safety/Environmental, Lilly Research Laboratories, Indianapolis, IN, USA.
  • Kemper R; Vertex Pharmaceuticals Incorporated, 50 Northern Ave, Boston MA, USA.
  • O'Leary-Steele C; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.
  • Parenty A; Novartis Pharma AG, Pre-clinical Safety, Werk Klybeck, CH-4057 Basel, Switzerland.
  • Spirkl HP; Sanofi-Aventis Deutschland GmbH, R&D DSAR/Preclinical Safety FF, Industriepark Hoechst, Bldg. H823, D-65926 Frankfurt am Main, Germany.
  • Stalford SA; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.
  • Weiner SK; Janssen Research & Development, 1400 McKean Road, Spring House, PA 19477, USA.
  • Wichard J; Bayer Pharma AG, Investigational Toxicology, Muellerstr. 178, S 116, D-13353, Berlin, Germany.
Regul Toxicol Pharmacol ; 76: 79-86, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26785392
ABSTRACT
At the confluence of predictive and regulatory toxicologies, negative predictions may be the thin green line that prevents populations from being exposed to harm. Here, two novel approaches to making confident and robust negative in silico predictions for mutagenicity (as defined by the Ames test) have been evaluated. Analyses of 12 data sets containing >13,000 compounds, showed that negative predictivity is high (∼90%) for the best approach and features that either reduce the accuracy or certainty of negative predictions are identified as misclassified or unclassified respectively. However, negative predictivity remains high (and in excess of the prevalence of non-mutagens) even in the presence of these features, indicating that they are not flags for mutagenicity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Simulação por Computador / DNA Bacteriano / Modelos Moleculares / Mutagênese / Relação Quantitativa Estrutura-Atividade / Testes de Mutagenicidade / Mutação Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Simulação por Computador / DNA Bacteriano / Modelos Moleculares / Mutagênese / Relação Quantitativa Estrutura-Atividade / Testes de Mutagenicidade / Mutação Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Ano de publicação: 2016 Tipo de documento: Article